Cargando…

Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis

Chemoresistance is a poor prognostic factor in breast cancer and is a major obstacle to the successful treatment of patients receiving chemotherapy. However, the precise mechanism of resistance remains unclear. In this study, a pair of breast cancer cell lines, MCF-7 and its adriamycin-resistant cou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhipeng, Liang, Shuang, Lian, Xin, Liu, Lei, Zhao, Shu, Xuan, Qijia, Guo, Li, Liu, Hang, Yang, Yuguang, Dong, Tieying, Liu, Yanchen, Liu, Zhaoliang, Zhang, Qingyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377623/ https://www.ncbi.nlm.nih.gov/pubmed/25818003 http://dx.doi.org/10.1038/srep09301

Ejemplares similares

Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis
por: Dong, Tieying, et al.
Publicado: (2017)

Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
por: Wang, Yunxuan, et al.
Publicado: (2018)

The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma
por: Dong, Tieying, et al.
Publicado: (2015)

Identification of adriamycin resistance genes in breast cancer based on microarray data analysis
por: Chen, Yan, et al.
Publicado: (2020)

Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway
por: Yang, Yuguang, et al.
Publicado: (2018)

Jagged1 modulated tumor-associated macrophage differentiation predicts poor prognosis in patients with invasive micropapillary carcinoma of the breast
por: Liu, Hang, et al.
Publicado: (2017)

The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
por: Ji, Hongfei, et al.
Publicado: (2016)

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
por: Cao, Bei, et al.
Publicado: (2013)

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients
por: Wang, Jingxuan, et al.
Publicado: (2015)

Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer
por: Wang, Jingxuan, et al.
Publicado: (2013)

Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells
por: Feng, Fan, et al.
Publicado: (2018)

Impact of ethyl pyruvate on Adriamycin-induced cardiomyopathy in rats
por: Liu, Menglin, et al.
Publicado: (2016)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
por: Ji, Hongfei, et al.
Publicado: (2015)

USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin
por: Qin, Tao, et al.
Publicado: (2021)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

A Novel Resveratrol-Arsenic Trioxide Combination Treatment Synergistically Induces Apoptosis of Adriamycin-Selected Drug-Resistant Leukemia K562 Cells
por: Chen, Jing, et al.
Publicado: (2019)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
por: Zhang, Minghui, et al.
Publicado: (2016)

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer
por: Ren, Boxue, et al.
Publicado: (2019)

Ophiobolin-O Reverses Adriamycin Resistance via Cell Cycle Arrest and Apoptosis Sensitization in Adriamycin-Resistant Human Breast Carcinoma (MCF-7/ADR) Cells
por: Sun, Wenxia, et al.
Publicado: (2013)

Label-Free Quantitative Proteomics Analysis of Adriamycin Selected Multidrug Resistant Human Lung Cancer Cells
por: Efeoglu, Esen, et al.
Publicado: (2022)

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.
por: Citro, G., et al.
Publicado: (1991)

PLAC8 promotes adriamycin resistance via blocking autophagy in breast cancer
por: Chen, Yongxia, et al.
Publicado: (2021)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Protective effect of astragalosides from Radix Astragali on adriamycin-induced podocyte injury
por: Sai, Yi-Pa, et al.
Publicado: (2018)

Downregulated miR-130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin
por: Liu, Huimin, et al.
Publicado: (2020)

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
por: He, Ye, et al.
Publicado: (2015)

Metastatic Metaplastic Breast Cancer Successfully Treated with Adriamycin and Cisplatin
por: Hayashino, Kenta, et al.
Publicado: (2022)

Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations
por: Coldwell, Kate E., et al.
Publicado: (2008)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line
por: Li, Jie, et al.
Publicado: (2001)

NBDHEX re‐sensitizes adriamycin‐resistant breast cancer by inhibiting glutathione S‐transferase pi
por: Sha, Huanhuan, et al.
Publicado: (2022)

Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells
por: XIE, XIAO-HONG, et al.
Publicado: (2014)

Effects of the Combination of Gliotoxin and Adriamycin on the Adriamycin-Resistant Non-Small-Cell Lung Cancer A549 Cell Line
por: Manh Hung, Le Van, et al.
Publicado: (2018)

Acute Induction of Adriamycin‐resistance in Human Colon Carcinoma HT‐29 Cells Exposed to a Sublethal Dose of Adriamycin
por: Tomida, Akihiro, et al.
Publicado: (1995)

Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer
por: Ma, Siping, et al.
Publicado: (2018)

Endothelin Receptor A Blockade Is an Ineffective Treatment for Adriamycin Nephropathy
por: Tan, Roderick J., et al.
Publicado: (2013)

Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer
por: Zhang, Xiangyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_urr1nau0qq8je9grls5hvq9qit